Table I.

Demographic data and clinical features of 200 patients with COVID-19–associated cutaneous manifestations

Analyzed parameters	Values
Age at the time of the onset of COVID-19, y, median (IQR)	57 (40.25-72.25)
Male, n (%)	108 (54)
Female, n (%)	92 (46)
Latency between cutaneous manifestations and systemic symptoms, days, median (IQR)∗	14 (4-27)
Duration of cutaneous manifestations, days, median (IQR)†	12 (8-20)
Cutaneous phenotypes, n (%)
Urticarial rash‡	19 (10.2)
Confluent erythematous/maculopapular/morbilliform rash‡	48 (25.7)
Papulovesicular exanthem‡	29 (15.5)
Chilblain-like acral pattern‡	46 (24.6)
Livedo reticularis-like/racemosa-like pattern‡	4 (2.1)
Purpuric vasculitic pattern‡	13 (6.9)
Other cutaneous phenotypes‡	28 (15)
More than 1 phenotype	13 (6.5)
Duration of cutaneous manifestations, days, median (IQR)
Urticarial rash	8 (5-13)§
Confluent erythematous/maculopapular/morbilliform rash	10 (7-14.5)װ
Papulovesicular exanthem	10 (7-14)¶
Chilblain-like acral pattern	22 (15-32)#
Livedo reticularis/racemosa-like pattern	14 (5-27)∗∗
Purpuric vasculitic pattern	11 (6.5-15.5)††
Latency between cutaneous manifestations and systemic symptoms, days, median (IQR)
Urticarial rash	12 (5-23)‡‡
Confluent erythematous/maculopapular/morbilliform rash	21.5 (12-28.75)§§
Papulovesicular exanthem	4 (1.25-8)װװ
Chilblain-like acral pattern	16 (9-39)¶¶
Livedo reticularis/racemosa-like pattern	24.5 (4-48.25)##
Purpuric vasculitic pattern	16 (3.5-34)∗∗∗
Skin-related symptoms, n (%)
Pruritus	81 (40.5)
Pain/burning	22 (11)

Data were available for the following numbers of patients: 155,^∗ 171,^† 19,^§ 49,^ǁ 21,^¶ 43,^# 5,^∗∗ 17,^†† 24,^‡‡ 44,^§§ 28,^ǁǁ 23,^¶¶ 6,^## and 17.^∗∗∗

^‡Percentages of 187 patients (excluding the 13 with more than 1 cutaneous phenotype).